Lumira Ventures Research
Investment Thesis
Lumira Ventures is Canada's largest and most active dedicated life sciences venture capital investor, with a multi-stage healthcare investment platform spanning Toronto, Montreal, Vancouver, and Boston. The firm partners with mission-driven entrepreneurs and diverse teams to build transformative biotherapeutic and medical device companies, with performance measured not only by financial returns but by patient impact: the firm cites over 1 billion patient lives touched, 40+ diseases targeted, 50+ approved products, and 100+ companies funded since its founding. Lumira traces its roots to 2007, when its partners completed a management buyout of MDS Capital and rebranded as Lumira Ventures, giving the team a track record spanning nearly two decades.
Sector Focus
Lumira invests exclusively in healthcare: biotherapeutics and medical devices across a broad range of indications with high unmet clinical need. Recent and historical portfolio activity spans oncology (Altis Labs, Sound Blade Medical, HistoSonics), neurology and neuromodulation (Nervonik, Axonis Therapeutics, Cadence Neuroscience, Navion Neurosciences), reproductive health (Contraline), metabolic disease (Endogenex), rare disease and immunology (Congruence Therapeutics, Aurinia Pharmaceuticals, X4 Pharmaceuticals), and diagnostics/imaging devices (Exact Imaging, SpectraWAVE, BardyDx). The firm also runs the Cancer Breakthrough Fund, a dedicated oncology vehicle launched in partnership with the Terry Fox Foundation and the Canadian Cancer Society.
Stage Focus
Lumira invests across the development continuum for therapeutics, and from late clinical stage through revenue-generation for medical devices. Recent rounds show participation from Series A through Series C, and the firm has historically been involved from early venture rounds through pre-IPO and strategic financings.
Check Size
Explicit typical check size is not disclosed on the firm's public materials. Recent syndicated rounds Lumira has joined range from roughly $25M (Altis Labs Series A) to $92.5M (Contraline Series B), consistent with a life-sciences investor writing meaningful but not sole-anchor checks alongside co-investors such as OrbiMed, Qiming Venture Partners USA, BVF Partners, and RA Capital Management.
Lead Tendency
Lumira has both led and co-led rounds historically (e.g., co-led HistoSonics' 2019 Series C alongside J&J Innovation and Varian Medical Systems; co-led Sound Blade Medical's Series A with Amzak Health) and has also participated as a syndicate member in larger rounds led by specialist life-sciences investors (Nervonik, Contraline, Altis Labs).
Recent Activity
Lumira closed the first close of its fifth flagship fund, Lumira Ventures V, in April 2026, targeting a final size of US$200M (C$275M) to back healthcare innovation across North America, with an explicit focus on expanding into secondary (non-coastal) North American venture ecosystems. Fund V's first investment was a US$52.5M Series B in Nervonik (peripheral nerve stimulation), closed within days of the fund's first close. The firm's Cancer Breakthrough Fund also closed oversubscribed in May 2026, having launched roughly a year earlier, and has made investments in Sound Blade Medical and Altis Labs. Since 2024, Lumira reports 7 portfolio exits at a cumulative transaction value exceeding US$8B, highlighted by HistoSonics' US$2.25B majority-stake acquisition in August 2025 by a consortium including Wellington Management, K5 Global, and Bezos Expeditions — the firm's highest-returning investment to date, for which Lumira won the CVCA's 2026 VC Global Dealmaker Award.
Portfolio Highlights
Notable historical exits include Mako Surgical (acquired by Stryker), Pharmasset (acquired by Gilead, 2011), Morphotek (acquired by Eisai, 2007), BardyDx (acquired by Hillrom, 2021), and OpSens (acquired by Haemonetics, 2021). The active portfolio includes HistoSonics (histotripsy cancer therapy, ~US$150M revenue run-rate), Contraline (male contraceptive, Phase 3-bound), Aurinia Pharmaceuticals and Zymeworks (public biotechs), and G1 Therapeutics (public oncology biotech), alongside a deep bench of earlier-stage biotech and medtech companies spanning oncology, neurology, and rare disease.
Team
- Gerry Brunk, MBA — Managing Partner (named April 2026; previously co-founder)
- Peter van der Velden, MBA, M.Sc. — Executive Chairman (transitioned from prior leadership role April 2026)
- Lu Han, Ph.D. — Partner
- Nikhil Thatte — Partner
- Jacki Jenuth, Ph.D. — Partner and Chief Operating Officer
- Suman Rao, Ph.D. — Principal
- Beni Rovinski, Ph.D. — Managing Director
- Daniel Hétu, M.D., MBA — Managing Director
- Isabelle Harris — Associate (promoted April 2026)
- Danielle Karakas, Ph.D. — Analyst
- Vasco Larcina, CPA, CA — CFO
Decision Process
The firm describes a partnership-style, consensus-driven process: "each investment is done the right way - based on a process of sound diligence, collaboration, and encouraging alternative views, while ultimately being tied to a consensus decision."
Founder Preferences
Lumira explicitly seeks mission-driven founders and diverse teams building products with high unmet clinical need, and values engaged, value-adding relationships with management teams post-investment (board-level support, network access to physicians, hospitals, and strategic partners).
Geographic Focus
North America, with a stated strategic emphasis on secondary venture ecosystems beyond the coastal hubs, and offices in Toronto (HQ), Montreal, Vancouver, and Boston.